November 19, 2025 by admin aurigene Development of a Differentiated, Best-in-Class oral Cbl-b inhibitor with Robust Immune Activation and Favourable Safety for Cancer Immunotherapy
November 19, 2025 by admin aurigene Discovery and preclinical characterization of novel macrocyclic KIF18A inhibitors for treatment of chromosomally instable tumors
November 19, 2025 by admin aurigene Discovery and development of a highly differentiated, efficacious, first-in-class anti-SIRPα/β dual antibody with single agent phagocytosis activity
November 19, 2025 by admin aurigene Identification of an orally bio-available SMARCA2 selective degrader for treatment of SMARCA4 mutant cancers
June 5, 2025 by admin aurigene Discovery and development of a highly cooperative and potent pan-KRAS degrader
June 5, 2025 by admin aurigene Discovery of highly selective, potent and orally bio-available SMARCA2 degraders
June 5, 2025 by admin aurigene Identification of first-in-class paralog selective SMARCA4 degraders for treatment of haematological and prostate malignancies
September 25, 2024 by admin aurigene Efficacy of a First-in-Class Polymerase Theta Degrader in Preclinical Cancer Models
September 24, 2024 by admin aurigene Discovery and Development of pan-KRAS Degraders for Cancer Therapy
September 2, 2024 by admin aurigene Distinctive Roles for Small Molecule Inhibitors of Immune Checkpoint Proteins (LE072)
